Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 132,524 Shares of Company Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 132,524 shares of the firm’s stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $30.52, for a total value of $4,044,632.48. Following the sale, the insider directly owned 167,438 shares of the company’s stock, valued at $5,110,207.76. This represents a 44.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.59, for a total value of $4,525,301.06.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.33, for a total value of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total value of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.89, for a total transaction of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total transaction of $1,988,880.72.
• On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total transaction of $3,674.72.
• On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.73, for a total transaction of $4,812,181.01.

Alamar Biosciences Stock Performance

Alamar Biosciences stock opened at $31.93 on Wednesday. Alamar Biosciences, Inc. has a 12-month low of $18.84 and a 12-month high of $39.61. The company’s fifty day moving average is $30.73.

Alamar Biosciences (NASDAQ:ALMR) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.14. The company had revenue of $29.43 million during the quarter. On average, equities research analysts expect that Alamar Biosciences, Inc. will post -1.22 EPS for the current fiscal year.

Institutional Trading of Alamar Biosciences

Hedge funds have recently bought and sold shares of the business. Braidwell LP bought a new stake in Alamar Biosciences during the 2nd quarter valued at $29,365,000. Wellington Management Group LLP acquired a new position in Alamar Biosciences during the second quarter worth $12,407,000. State Street Corp acquired a new position in Alamar Biosciences during the second quarter worth $3,930,000. Finally, Squarepoint Ops LLC bought a new position in shares of Alamar Biosciences in the second quarter valued at $283,000.

Analyst Ratings Changes

ALMR has been the subject of several research reports. TD Cowen restated a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Stifel Nicolaus upped their price target on Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Weiss Ratings lowered Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. Finally, JPMorgan Chase & Co. increased their price target on Alamar Biosciences from $32.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Alamar Biosciences presently has a consensus rating of “Hold” and an average target price of $31.80.

About Alamar Biosciences

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.